Pluripotent Stem Cell-Based Platforms in Cardiac Disease Modeling and Drug Testing

Clin Pharmacol Ther. 2017 Aug;102(2):203-208. doi: 10.1002/cpt.722.


The ability to generate patient/disease-specific human pluripotent stem cell (hPSC)-derived cardiomyocytes (hPSC-CMs) brings a unique value to the fields of cardiac disease modeling, drug testing, drug discovery, and precision medicine. Further integration of emerging innovative technologies such as developmental-biology inspired differentiation into chamber-specific cardiomyocyte subtypes, genome-editing, tissue-engineering, and novel functional phenotyping methodologies should facilitate even more advanced investigations. Here, we review cornerstone concepts and recent highlights of hPSC-based cardiac disease modeling and drug testing.

Publication types

  • Review

MeSH terms

  • Animals
  • Cardiovascular Agents / pharmacology
  • Cardiovascular Agents / therapeutic use
  • Drug Discovery / methods*
  • Drug Evaluation, Preclinical / methods
  • Heart Diseases / drug therapy*
  • Heart Diseases / pathology
  • Heart Diseases / physiopathology
  • Humans
  • Induced Pluripotent Stem Cells / drug effects
  • Induced Pluripotent Stem Cells / physiology
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / physiology
  • Pluripotent Stem Cells / drug effects*
  • Pluripotent Stem Cells / physiology


  • Cardiovascular Agents